DSM buys Upfront's Rhobust chromatography tech
DSM Biologics says combining its XD platform with newly-acquired Rhobust chromatography platform will create high yield, low cost bio-manufacturing option.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs